Proprietary non-viral vector platform to deliver genes to mucosal cells lining the gut
enGene, Inc., a biotechnology company, develops a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. It develops a non-integrating biopolymer-based nucleotide (DNA and siRNA) delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. Its platform technology impacts diseases of mucosal tissues, such as the gastrointestinal tract, lung, and bladder, as well as provides systemic release of proteins from the gut to treat diabetes, anemia, hemophilia, and others. enGene, Inc. has a strategic alliance with Takeda Pharmaceutical Company Ltd. The company was founded in 1999 and is based in Vancouver, Canada.